| Primary information |
|---|
| sequence ID | Seq_3553 |
| Peptide sequence | HTFMGVVSLGSPSGEVSHPRKT |
| CancerPDF_ID | CancerPDF_ID1674, CancerPDF_ID1675, CancerPDF_ID3211, CancerPDF_ID3212, CancerPDF_ID9648, CancerPDF_ID9649, CancerPDF_ID12694, |
| PMID | 21136997,21136997,21136997,21136997,21533267,21533267,27058005 |
| Protein Name | Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein |
| UniprotKB Entry Name | FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN |
| Fluid | Serum,Serum,Plasma,Plasma,Serum,Serum,Serum |
| M/Z | 2309.15865,2325.15356,2309.1586,2325.1536,578.3,582.3,2326.204 |
| Charge | 1,1,1,1,4,4,NA |
| Mass (in Da) | NA,NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,NA,NA,NA,1.49,1.49,NA |
| CancerPDF_ID | CancerPDF_ID1674, CancerPDF_ID1675, CancerPDF_ID3211, CancerPDF_ID3212, CancerPDF_ID9648, CancerPDF_ID9649, CancerPDF_ID12694, |
| p-Value | NA,NA,NA,NA,NA,NA,"less than 0.001,0.071,0.058" |
| Software | MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,Proteome Discoverer |
| Length | 22,22,22,22,22,22,22 |
| Cancer Type | Colorectal cancer,Colorectal cancer,Normal,Normal,Lung adenocarcinoma,Lung adenocarcinoma,Breast cancer |
| Database | SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4),SwissProt Database |
| Modification | NA,Oxidation of Met,NA,Oxidation of Met,NA,Oxidation,NA |
| Number of Patients | 30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 0.58 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.217 fold change" |
| Validation | Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates,NA |
| Sensitivity | NA,NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |